【Objective】To evaluate the comprehensive prognosis effect of piribedil and Madopar for the treatment of early Parkinson's syndrome when administered. 【Methods】Sixtyfour patients with early Parkinson's syndrome in our hospital were selected as the research object. According to the random number table method, the patients were divided into two groups (n=32). Group A were treated with piribedil and Group B were treated with Madopar. Before and after treatment, 99mTcTRPDAT1 specific uptake value, UPDRS (Parkinson's disease) and clinical efficacy of patients in the two groups were tested and compared through dopamine transportersingle photon emission computed tomography (TRODATSPECT). 【Results】 At 6 months and 10 months after treatment, the UPDRS in the two groups were significantly reduced compared to before treatment . After 6 months and 10 months of treatment， the UPDRS scores in Group A were significantly lower than those in Group B (P<0.05). The specific uptake values of  99mTcTRODAT1 on the ipsilateral and contralateral side of the patients in Group A were significantly lower than those in Group B (P<0.05). The therapeutic effect rate and total effective rates in Group A were 40.63% and 90.63% respectively, which were significantly higher than  25.00% and 65.62% in Group B (P<0.05). The incidence of adverse reactions in Group A was 18.75%, which was significantly lower than 31.25% in Group B (P<0.05). 【Conclusion】In the clinical treatment of early Parkinson's syndrome, taking Madopar alone can accelerate the apoptosis of dopaminergic neurons and promote disease progression, while taking piribedil does not impact the prognosis of patients or cause adverse effects.